According to reports, although estrogen replacement therapy commonly used in Western medicine can supplement the levels of downregulated E2 and reduce the levels of upregulated FSH, LH, and the risk of cardiovascular events and osteoporosis-related fractures in patients with POF, but when used alone or for a long time, there are many problems after treatment, such as high ovulation rate, low live birth rate, high recurrence rate, poor prognosis, ovarian hyperstimulation syndrome, and high risk of breast cancer [14–16]. This evidence concerns the gene PLOD1 and breast cancer.